Sareum Holdings PLC's (LON:SAR) Tim Mitchell caught up with Proactive London's Andrew Scott following the news it's raised just over £1mln to advance the preclinincal work on its TYK2/JAK1 drugs SDC-1801 and SDC-1802.
Mitchell says they're exploring the potential benefit of the TYK2/JAK1 inhibitors against coronavirus (COVID-19) as well as in cancer and autoimmune diseases.
Preparatory work is being made to advance candidates towards human trials.